Serious complications of hypertrophic cardiomyopathy (HCM) may include atrial fibrillation (AFib), stroke, heart failure, and mortality1-3

An investigation of a community-based population of 480 patients with HCM found that:4

Patients with HCM were up to

6x

more likely to
develop AFib

Ischemic strokes were

8x

more frequent in
these
patients
with AFib

22-43%

of patients with HCM developed heart failure5,6

3x

higher risk of mortality in older
patients (aged 50 to 69 years) with
HCM vs. the general population5

4x

higher risk of mortality in younger
patients (aged 20 to 29 years) with HCM
vs. the general population5

    HCM is the leading cause of sudden cardiac death (~1%) in younger patients1-3

HCM increases the risk of certain comorbidities as well as mortality in patients of all ages1-3

Impact on daily life

References

Hide references
  1. Naidu, Srihari S, editor. Hypertrophic Cardiomyopathy. Second ed., Springer International Publishing, 2019.
  2. Gersh BJ, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy. J Thorac Cardiovasc Surg. 2011;142(6):e153-203.
  3. Ommen SR, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2020;142(25):e558-e631.
  4. Olivotto I, et al. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation. 2001;104(21):2517-24.
  5. Ho CY, et al. Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRE). Circulation. 2018;138(14):1387-98.
  6. Rowin EJ, et al. Interaction of adverse disease related pathways in hypertrophic cardiomyopathy. Am J Cardiol. 2017;120(12):2256-64.